A prospective study of first-degree relatives of patients with MS found that this high-risk population faces significantly ...

“MASLD and T2DM represent intersecting global epidemics with substantial clinical and public health implications,” wrote the ...

The authors argue that sustainable drug pricing reform should focus on patient-centered value, not price alone. IRP is a ...

In Perioperative Immunotherapy Advances: Insights from CheckMate-77T and KEYNOTE-671, our panel delves into the following ...

Grinspoon noted that even incremental reductions in blood pressure incidence can translate into meaningful declines in ...

Mitochondrial DNA heteroplasmy is independently associated with an increased risk of CLL, suggesting potential as a novel biomarker for early risk identification.

EMBRACE reported 12-month suppression rates of 94% (IV N6LS+CAB LA), 82% (SC), and 88% (oral SOC), with no virologic failures and no new clinically significant AEs after month 6. Presentations focused ...

Julie Rosenthal, MD, MS, discusses the future direction of research into treating age-related macular degeneration.

To bridge the gap between clinical exuberance and evidence-based practice, Todd Brown, MD, PhD, an endocrinologist and clinical investigator at Johns Hopkins University, sat down at the Conference on ...

Todd T. Brown, MD, PhD, serves as an endocrinologist and clinical investigator at Johns Hopkins Medical Center. At CROI 2026, experts weigh GLP‑1 drugs in HIV aging—titration tips, surgery precautions ...

Steven Grinspoon, MD, is the chief of the Metabolism Unit at Massachusetts General Hospital, director of the Nutrition Obesity Research Center and professor of medicine at Harvard Medical School. The ...

FDA authorized desmopressin acetate oral solution (Desmoda) for CDI/AVP-D across all ages, representing the first FDA-approved oral liquid desmopressin formulation in the United States.